Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High – Here’s Why

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s share price hit a new 52-week high during mid-day trading on Thursday. The stock traded as high as $116.85 and last traded at $112.44, with a volume of 2702748 shares. The stock had previously closed at $115.13.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HALO. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Citizens Jmp lifted their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a report on Friday, August 7th. HC Wainwright reissued a “buy” rating and issued a $115.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, September 2nd. Finally, UBS Group restated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Trading Down 1.1%

The company’s 50 day simple moving average is $100.39 and its two-hundred day simple moving average is $79.89. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a market capitalization of $12.93 billion, a price-to-earnings ratio of 34.00, a P/E/G ratio of 0.44 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same period in the prior year, the firm posted $1.54 earnings per share. The business’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $107.24, for a total transaction of $2,144,800.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,336,727.20. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 91,474 shares of company stock worth $9,416,633 in the last three months. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HALO. QRG Capital Management Inc. raised its stake in Halozyme Therapeutics by 11.1% in the 2nd quarter. QRG Capital Management Inc. now owns 6,626 shares of the biopharmaceutical company’s stock worth $519,000 after acquiring an additional 662 shares during the last quarter. Talon Private Wealth LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter worth about $839,000. Sequoia Financial Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter worth about $359,000. Tidal Investments LLC lifted its holdings in shares of Halozyme Therapeutics by 13.5% during the second quarter. Tidal Investments LLC now owns 190,305 shares of the biopharmaceutical company’s stock worth $14,895,000 after purchasing an additional 22,707 shares during the period. Finally, WINTON GROUP Ltd lifted its holdings in shares of Halozyme Therapeutics by 704.6% during the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock worth $4,723,000 after purchasing an additional 52,848 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.